Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909091 | 0.88 | BTK (0.34) | S1PR2NPC1PIK3CA | |
| SCHEMBL23915420 | 0.85 | S1PR2 (0.33) | S1PR2 | |
| SCHEMBL23915356 | 0.82 | S1PR2 (0.39) | S1PR2NPC1 | |
| SCHEMBL23908980 | 0.81 | S1PR2 (0.34) | S1PR2NPC1 | |
| SCHEMBL23909084 | 0.80 | S1PR2 (0.35) | S1PR2NPC1 | |
| SCHEMBL23915604 | 0.79 | ADRA1A (0.37) | S1PR2NPC1 | |
| SCHEMBL23915441 | 0.79 | S1PR2 (0.35) | S1PR2NPC1 | |
| SCHEMBL23914613 | 0.79 | S1PR2 (0.37) | S1PR2NPC1 | |
| SCHEMBL23908919 | 0.79 | S1PR2 (0.35) | S1PR2 | |
| SCHEMBL23915620 | 0.78 | S1PR2 (0.41) | S1PR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885NPC1 467/4885P2RX3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.